Insular and Anaplastic Carcinoma of the Thyroid
- 1 March 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 231 (3), 329-338
- https://doi.org/10.1097/00000658-200003000-00005
Abstract
To analyze the clinicopathologic features of a large cohort of patients with insular or anaplastic carcinomas treated at a single institution. Insular and anaplastic carcinomas of the thyroid, although uncommon, have more aggressive clinical behavior than well-differentiated carcinomas of the thyroid. In the literature, the incidence and features of these carcinomas have not been fully characterized. The authors reclassified 740 primary thyroid carcinomas diagnosed and treated between January 1, 1954, and December 30, 1998, to select those with features that met the histologic criteria of insular or anaplastic carcinoma. The clinicopathologic features of these carcinomas were studied and compared. The expression of p53 and p21 in these tumors was analyzed by immunohistochemistry. Twenty-two patients (5 men, 17 women) with insular carcinoma and 38 patients (7 men, 31 women) with anaplastic carcinoma were found. Patients with insular carcinomas were younger (mean age 45 vs. 70 years) and had smaller tumors than those with anaplastic carcinomas (mean diameter 5 vs. 8 cm). Insular carcinomas were commonly mislabeled as other histologic subtypes, whereas anaplastic carcinomas might be overdiagnosed on pathologic examination. A history of longstanding goiter (>10 years) was noted in 27% of patients with insular carcinoma and 24% of patients with anaplastic carcinomas. Concomitant well-differentiated carcinomas of the thyroid were noted in 59% of patients with insular carcinoma and 39% of patients with anaplastic carcinoma. In anaplastic carcinomas, 13% of patients had concomitant insular carcinoma. Calcification or bone was noted in the stroma of 23% of patients with insular carcinomas and 47% of those with anaplastic carcinomas. The 10-year survival rates for patients with insular carcinoma and anaplastic carcinoma were 42% and 3%, respectively. Distant metastases were seen in 32% of patients with insular carcinoma and in 47% of patients with anaplastic carcinomas. In both types of carcinomas, metastatic tumors were often seen in bone and lung. Distant metastases were noted in a variety of organs in anaplastic carcinomas. In insular carcinoma, neither p53 nor p21 expression was present. In anaplastic carcinoma, p53 and p21 expression was identified in 69% and 3%, respectively. Concomitant expression of p53 and p21 was noted in one tumor. Insular carcinoma and anaplastic carcinoma had distinctive clinicopathologic features, and recognition of these histologic variants is important for better management of these tumors in the future. p53 overexpression might have a role in dedifferentiation from insular carcinoma to anaplastic carcinoma.Keywords
This publication has 49 references indexed in Scilit:
- Clinical Forms of Presentation and Evolution of Diffuse Sclerosing Variant of Papillary Carcinoma and Insular Variant of Follicular Carcinoma of the ThyroidThyroid®, 1998
- Apoptosis in thyroid neoplasms: relationship with p53 and bcl‐2 expressionHistopathology, 1998
- p53 gene mutation in thyroid carcinomaCancer Letters, 1996
- Lack of p16/CDKN2 alterations in thyroid carcinomasCancer Letters, 1996
- p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas.Journal of Clinical Pathology, 1994
- Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid glandThe Journal of Pathology, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- p53 mutations in all stages of thyroid carcinomasJournal of Clinical Endocrinology & Metabolism, 1993
- Genetic Alterations in Thyroid Tumor Progression: Association with p53 Gene MutationsJapanese Journal of Cancer Research, 1993
- p53 Gene Mutations Associated with Anaplastic Transformation of Human Thyroid CarcinomasJapanese Journal of Cancer Research, 1992